• Oncoinvent raised NOK 148.5 million in gross proceeds through a private placement, according to its third-quarter 2026 business update.
• The ovarian Phase 2 trial recruited 16 patients, bringing total enrollment to 71 by quarter-end.
• One additional clinical site brought the trial's recruiting network to 11 sites.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncoinvent ASA published the original content used to generate this news brief via Cision (Ref. ID: 202610280204BITN____UKPR__EN_20261027-BIT-0884-0) on October 28, 2026, and is solely responsible for the information contained therein.